Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PAM | P19021 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132540 | 0.85 | HDAC1 (0.37) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27845350 | 0.83 | MEN1 (0.33) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL949316 | 0.83 | HDAC1 (0.36) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL535279 | 0.83 | HDAC1 (0.36) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL126977 | 0.82 | ALDH1A1 (0.44) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL20872192 | 0.80 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4774409 | 0.80 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12905043 | 0.79 | GAA (0.44) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL20872178 | 0.78 | HDAC3 (0.45) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12914655 | 0.78 | RECQL (0.35) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-24 | — | — | US | disclosed |
| US-20140328919-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140286873-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | CERULEAN PHARMA INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130202659-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-09-29 | — | — | US | disclosed |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | CERULEAN PHARMA INC (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2011-08-04 | — | — | US | disclosed |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100247668-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058971-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | CYP1A2 3222/4885HDAC3 1573/4885HDAC1 2187/4885 |
| US-20130202659-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20160082111-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | CYP1A2 3222/4885HDAC3 1573/4885HDAC1 2187/4885 |
| US-20140274947-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | CYP1A2 3222/4885HDAC3 1573/4885HDAC1 2187/4885 |
| US-20120225825-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | CYP1A2 3222/4885HDAC3 1573/4885HDAC1 2187/4885 |
| US-20130196946-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | CYP1A2 3222/4885HDAC3 1573/4885HDAC1 2187/4885 |
| US-20110237540-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | SDCBP, DDOST, DSC1 | CYP1A2 3222/4885HDAC3 1573/4885HDAC1 2187/4885 |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20110268658-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20140286873-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20110262490-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | CYP1A2 2532/4885HDAC3 369/4885HDAC1 317/4885 |
| US-20100247668-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | CYP1A2 2532/4885HDAC3 369/4885HDAC1 317/4885 |
| US-20140328919-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20120282306-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20110237686-A1 | FORMULATIONS AND METHODS OF USE | LPXN, LIPA, CHMP4B | CYP1A2 3561/4885HDAC3 3343/4885HDAC1 4438/4885 |
| US-20140193510-A1 | Polymer-Agent Conjugates, Particles, Compositions, and Related Methods of Use | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
| US-20110189092-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | CYP1A2 3438/4885HDAC3 2457/4885HDAC1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.